Can Targeting NADP+ Metabolism Serve as a Therapeutic Strategy?
Targeting NADP+ metabolism represents a promising therapeutic strategy. Inhibiting key enzymes involved in NADPH production, such as glucose-6-phosphate dehydrogenase (G6PD) in the pentose phosphate pathway, could selectively impair cancer cell growth by disrupting their redox balance and synthetic capabilities. Additionally, inhibiting NADPH-dependent antioxidant systems may sensitize cancer cells to chemotherapy and radiotherapy.
